AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05833061 — intervention group
Intervention type: OTHER
Intervention: The Stroke Self-Efficacy Questionnaire (SSEQ)
Description: The Stroke Self-Efficacy Questionnaire (SSEQ) is a tool used to measure an individual's perceived self-efficacy or confidence in managing the consequences of a stroke. It consists of 13 items that assess an individual's ability to manage various stroke-related challenges, such as physical, emotional, and social difficulties. The SSEQ is designed to help healthcare professionals and researchers understand how an individual's perceived self-efficacy influences their ability to cope with the consequences of a stroke and manage their recovery effectively. By measuring an individual's perceived self-efficacy, the SSEQ can help identify areas where additional support and interventions may be needed to improve their overall recovery and quality of life.
Study NCT05906550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vascular access monitoring
Description: Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.
Study NCT05906550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vascular access monitoring
Description: Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.
Study NCT05906550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vascular access blood flow measurement
Description: Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume \<500mL/min.
Study NCT06508424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PulseOn
Description: PulseOn - 1 week washout period between interventions 75g crackers
Study NCT06508424 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wheat flour control
Description: Control -1 week washout period between interventions 75g crackers
Study NCT05192681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
Study NCT04922008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine and trastuzumab
Description: In IRIS-C cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given capecitabine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
Study NCT04922008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine and trastuzumab
Description: In IRIS-4 cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given vinorelbine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
Study NCT04918433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional anaesthesia
Description: Regional anaesthesia for sternotomy incision for congenital cardiac surgery
Study NCT06199375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine treatment
Description: The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)
Study NCT06199375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment
Description: The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)
Study NCT06199375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation training
Description: The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
Study NCT06199375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation training
Description: The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
Study NCT06199375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified mirror therapy
Description: The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
Study NCT05111431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride Nasal Spray
Description: In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray.
Study NCT05111431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine hydrochloride nasal spray blank preparation
Description: In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
Study NCT05575986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: Hetrombopag Olamine 7.5mg orally, once a day, for 14 days. This product should be taken on an empty stomach, 2 hours after oral administration before eating, avoid taking it with meals.
Study NCT04868162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003
Description: Administered intravenously
Study NCT05276401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Bisphosphocin Topical Gel
Description: Topical Gel
Study NCT05276401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Gel
Description: Topical Gel
Study NCT05276401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Bisphosphocin Topical Gel
Description: Topical Gel
Study NCT06544785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Oral Product
Description: Zanubrutinib drug product is supplied as 80 mg strengths in capsules for oral administration.~In both arms A and B, zanubrutinib 320 mg will be taken qDay with or without food. Patients will take zanubrutinib with water at approximately the same time every day.
Study NCT06544785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Each dose of obinutuzumab is 1000 mg administered intravenously, per institutional standards, with the exception of the first infusion in Cycle 2 (arm A) or Cycle 13 (arm B). It is recommended that the initial 1000 mg dose be administered over Day 1 (100 mg) and Day 2 (900 mg). For subjects who tolerate the initial 100 mg dose well and required no dose interruption or modification of the infusion rate, the treating physician may opt to administer the remaining 900 mg on Day 1.~Arm A: patients will receive obinutuzumab on days 1 (100 mg), 2 (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 2 of zanubrutinib treatment, and on the day 1 of cycles 3-7 (1000 mg).~Arm B: patients will receive obinutuzumab on days 1 (100 mg), 2 ( (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 13 of zanubrutinib treatment, and on the day 1 of cycles 14-18 (1000 mg).
Study NCT06242366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Intervention 2 phases Phases 1) In-hospital period (4 times and 30-60 mins/times) intervention includes Stroke education, Rehabilitation, environmental management, and complication prevention. Intervention participants will receive a booklet (choose between hard copy or electronic copy) self-care for stroke patients, Rehabilitation clip, and Self-care record form.~Phases 2) after hospital discharge 5 times (first times within 24 hours after hospital discharge) and (second-fifth time: 1 time/weekly)15-30 mins/times by Line Application for repeat and following education, rehabilitation complication prevention and finding limit to self-care management.
Study NCT05033886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: oral
Study NCT05033886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT05801146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection [HG102]
Description: Single administration, Day 0, 20 units
Study NCT05801146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: Single administration, Day 0, 20 units
Study NCT04787783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based preoperative assessment
Description: Preoperative assessment conducted through a web based application
Study NCT06158126 — intervention group
Intervention type: DRUG
Intervention: Initiating daily oral PrEP during pregnancy
Description: Group 1a, will include pregnant women who initiate oral PrEP at enrollment into the study.
Study NCT06158126 — intervention group
Intervention type: DRUG
Intervention: Already using daily oral PrEP at the time of pregnancy diagnosis
Description: Group 1b will include women already using daily oral PrEP at the time of pregnancy diagnosis and enrollment in the study.
Study NCT05677854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health literacy based motivaonal interview
Description: Motivational interviewing technique was used based on health literacy.
Study NCT05677854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health literacy based health education
Description: Health education based on health literacy was used.
Study NCT05307081 — intervention group
Intervention type: DRUG
Intervention: Artificial Tears
Description: Artificial Tears are an FDA approved intervention
Study NCT03598946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urinary test
Description: Women use a home urinary test themselves
Study NCT05680090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligent system for eye emergency triage and primary diagnosis
Description: An intelligent triage and diagnostic system for ophthalmic emergencies has been developed. In the prospective test, patients with acute ocular symptoms can achieve remote self-triage and primary diagnosis after uploading metadata and ocular images.
Study NCT05042570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: * This technique will be performed using instruments of different sizes, shapes and treatment styles.~* During the application, instruments will be applied to loosen the muscle tissue and fascia by gliding on the tissue at certain angles.~* The muscle groups to be treated with IASTM are gastrocnemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* The instrument will be sterilized before treatment.~* IASTM treatment will be applied without damaging the tissue after massaging cream is applied to the muscle fibers with the instrument.
Study NCT05042570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Exercises
Description: * The muscle groups to be applied stretching exercises are gastrocinemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* 3 different functional stretching exercises will be applied;~* With the hands supported on the wall and with the help of the physiotherapist, the affected extremity is behind the knee in full extension m. gastrocnemius stretching exercise,~* With the hands supported on the wall and with the help of the physiotherapist, the knee is partially flexed, with the affected extremity behind. soleus stretching exercise,~* It is a stretching exercise that will be applied by asking the patient to squat without lifting his heels, with the patient's hands supported by the physiotherapist.
Study NCT05042570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group / NDT program
Description: * Efforts to eliminate tone disorders,~* Sensory-perception-motor integrity development studies,~* Activities aimed at facilitating movements in daily life,~* Stretching and strengthening exercises due to muscle shortness and weakness,~* Studies to increase lower and upper extremity functionality,~* It will include the training of activities such as standing up, walking and balance.
Study NCT05652738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive cooling application
Description: Passive cooling application for asphyxiated neonates and their effect on myocardial function and hemodynamics
Study NCT05652738 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cooling using Blanket roll III
Description: standard care using Blanket roll III in asphyxiated neonates and their effect on myocardial function and hemodynamics
Study NCT05949567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urodynamic exam in sitting and lying position
Description: Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)
Study NCT05729503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Description: Cotton tip applicator pre-soaked with lidocaine
Study NCT05729503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cotton tip applicator pre-soaked with saline
Study NCT05162014 — intervention group
Intervention type: DRUG
Intervention: empagliflozin
Description: empagliflozin
Study NCT05162014 — intervention group
Intervention type: DRUG
Intervention: Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
Description: Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
Study NCT05953090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-0940
Description: A non-hormonal and non-steroidal gel that supports vulvovaginal mucosal conditions and speeds up recovery post vaginal rejuvenation. It is a suitable alternative to vaginally administered estrogen and topical corticosteroids, that promotes a moist healing environment leading to faster re-epithelialization. The gel relieves symptoms such as itchiness, tenderness, dryness, burning sensation, painful intercourse (dyspareunia), painful urination (dysuria), rectal and defecating pain. It improves erythema, mucosal tissue thinning, erosions, fissures, ulcerations, scarring/adhesions and swelling. It is indicated for long-term use to maintain the health of the vaginal mucosa without the side effects of vaginally administered hormonal therapy and topical corticosteroids.
Study NCT05022589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, \~30 minutes per session.
Study NCT05543408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXERCISE
Description: individualized, progressive, exercise program
Study NCT06498414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifampin standard arm
Description: 120 doses daily self-administered rifampin at 10mg/kg/day (max 600mg/day)
Study NCT06498414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin double dose
Description: 60 doses daily self-administered rifampin at 20 mg/kg (max. 1200 mg/day)
Study NCT06498414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin and rifapentine
Description: 30 doses daily self-administered levofloxacin (15 mg/kg, max 750mg/day and rifapentine (10mg/kg, max: 600mg)
Study NCT06536959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine
Description: For AML patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~For MDS patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 14 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~The venetoclax starting dose is 100 mg on the first day, ramping up to 200 mg on the second day and finally 400 mg once daily. The steady daily dose (after ramp-up phase) should be reduced to 100 mg (coadministered with moderate CYP3A inhibitors or P-gp inhibitors) and 70 mg (coadministered with strong CYP3A4 inhibitors).
Study NCT06148415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fetal Heartbeat Monitoring Group
Description: Fetal Heartbeat Monitoring Group
Study NCT06447311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid gel
Description: Hyaluronic acid is involved in tissue repair and wound healing by stimulating cell proliferation, migration and interaction with several growth factors. Furthermore, HA has a crucial role in space-filling owing to its hygroscopic nature.
Study NCT06447311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Hyaluronic acid is involved in tissue repair and wound healing by stimulating cell proliferation, migration and interaction with several growth factors. Furthermore, HA has a crucial role in space-filling owing to its hygroscopic nature.
Study NCT06080100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon
Description: inhalation of xenon in a sub-narcotic dosage
Study NCT06080100 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: premedication hydroxyzine 25 mg
Description: taking anxiolytic 30 minutes before surgery
Study NCT04632160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IASD System II
Description: The implant is placed across the interatrial septum using a percutaneous transcatheter approach.
Study NCT04839328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg Hemay005
Description: Hemay005 is a small molecule PDE4 inhibitor.
Study NCT04839328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebos are the same as drugs, but contain no Hemay005.
Study NCT05488106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05488106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 1.6mg/d
Description: Riboflavin 1.6mg/d
Study NCT05661864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Tiered Systems of Support for Teacher Training
Description: In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
Study NCT06158126 — intervention group
Intervention type: DRUG
Intervention: Initiating injectable PrEP during pregnancy
Description: Group 2a will include pregnant women who initiate injectable PrEP (CAB-LA) at enrollment into the study.
Study NCT06158126 — intervention group
Intervention type: DRUG
Intervention: Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis
Description: Group 2b will include women using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis.
Study NCT05541822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABN401
Description: Tablets~Route of Administration: Oral
Study NCT06233162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat-Test product
Description: Febuxostat 80 mg tablets Manufactured by: Zydus Lifesciences Limited, India
Study NCT06233162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat-Reference product
Description: Febuxostat 80 mg tablets Manufactured by: Patheon France, France